- Home
- BNTX vs ZTS Comparison
BNTX vs ZTS Comparison
Compare BNTX & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTX | ZTS |
|---|---|---|
| Founded | 2008 | 1952 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 29.0B |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BNTX | ZTS |
|---|---|---|
| Price | $88.20 | $80.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 18 |
| Target Price | ★ $116.75 | $93.47 |
| AVG Volume (30 Days) | 1.0M | ★ 2.9M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 2.58% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 3.08 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.50 | $2.43 |
| P/E Ratio | ★ N/A | $26.62 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $79.81 | $68.92 |
| 52 Week High | $124.00 | $147.93 |
Technical Indicators
Market Signals| Indicator | BNTX | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 68.01 |
| Support Level | $87.98 | $72.36 |
| Resistance Level | $94.18 | $82.66 |
| Average True Range (ATR) | 3.04 | 1.73 |
| MACD | -0.29 | 0.90 |
| Stochastic Oscillator | 6.64 | 87.52 |
Price Performance
Historical ComparisonAbout BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.